Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any acute myeloid leukemia that has the chromosomal anomaly FLT3 internal tandem duplication. (A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.)
Biomarker and diagnostic research for acute myeloid leukemia, FLT3 internal tandem duplication has been reported in the published literature.
No clinical trials have been registered for acute myeloid leukemia, FLT3 internal tandem duplication.
226 publications have been identified in PubMed for acute myeloid leukemia, FLT3 internal tandem duplication. Research spans Basic Science / Preclinical (23%), Gene Therapy / Novel Therapeutics (22%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 51 | 23% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:59 PM UTC
Common questions about acute myeloid leukemia, FLT3 internal tandem duplication
New treatment approaches |
49 |
22% |
Clinical study results | 41 | 18% |
Research summaries | 30 | 13% |
Testing and diagnosis research | 22 | 10% |
Disease patterns and progression | 19 | 8% |
Patient case studies | 14 | 6% |
Song L (2026). [PMID: 42015516](https://pubmed.ncbi.nlm.nih.gov/42015516/). *Eur J Haematol*. [Clinical Trial Publication]
Gu C (2026). [PMID: 42035942](https://pubmed.ncbi.nlm.nih.gov/42035942/). *Eur J Pharmacol*. [Epidemiology / Natural History]
Liu W (2026). [PMID: 41786054](https://pubmed.ncbi.nlm.nih.gov/41786054/). *Bioorg Med Chem Lett*. [Gene Therapy / Novel Therapeutics]
Chang YS (2026). [PMID: 41742883](https://pubmed.ncbi.nlm.nih.gov/41742883/). *Haematologica*. [Diagnostic / Biomarker]
Mawalankar G (2026). [PMID: 41719508](https://pubmed.ncbi.nlm.nih.gov/41719508/). *JCO Glob Oncol*. [Epidemiology / Natural History]
Duployez N (2026). [PMID: 42166362](https://pubmed.ncbi.nlm.nih.gov/42166362/). *Blood*. [Diagnostic / Biomarker]
Fu YH (2026). [PMID: 41702887](https://pubmed.ncbi.nlm.nih.gov/41702887/). *Cell Death Discov*. [Basic Science / Preclinical]
Lai A (2026). [PMID: 41411742](https://pubmed.ncbi.nlm.nih.gov/41411742/). *Neoplasia*. [Diagnostic / Biomarker]
Gao S (2026). [PMID: 41043203](https://pubmed.ncbi.nlm.nih.gov/41043203/). *European journal of medicinal chemistry*. [Review / Meta-Analysis]
Bruzzese A (2026). [PMID: 41923577](https://pubmed.ncbi.nlm.nih.gov/41923577/). *European journal of haematology*. [Review / Meta-Analysis]